Electroacupuncture Plus CBT-I for Sleep in Gynecologic Cancer

Key Takeaways

• During chemotherapy for gynecological cancer, participants with insomnia and anxiety symptoms had significantly greater modified-PSQI improvement with electroacupuncture plus CBT-I than with sham plus CBT-I.
• At Week 4, AIS ≤6 was reached by 71.1% versus 42.1%, and HAMA ≤14 by 92.1% versus 65.8%, in the active versus sham groups.
• Trial-defined overall response occurred in 92.1% of the electroacupuncture-plus-CBT-I arm versus 71.1% of the sham-plus-CBT-I arm.
• No serious adverse events occurred in either arm.

For patients undergoing chemotherapy for gynecological cancer, insomnia and anxiety can coexist and complicate supportive symptom care. Whether electroacupuncture adds benefit when behavioral insomnia therapy accompanies both active and sham procedures remains uncertain.

Investigators at the Obstetrics and Gynecology Hospital of Fudan University in Shanghai, China, enrolled patients in the Current Oncology trial of electroacupuncture plus CBT-I. The single-center, sham-controlled randomized trial included 76 patients aged 20–70 with histologically confirmed gynecological cancer, diagnosed insomnia, Hamilton Anxiety Rating Scale (HAMA) scores >14, and ongoing chemotherapy. Computer-generated, concealed allocation assigned 38 per arm; all completed four weeks. Participants and assessors were masked as reported, but acupuncturists were not. Both groups received weekly cognitive behavioral therapy for insomnia (CBT-I); active electroacupuncture or blunt-tip, nonpenetrating sham was delivered three times weekly for four weeks. The sham device appeared active but delivered no current. The prespecified primary endpoint was baseline-to-Week 4 change in modified Pittsburgh Sleep Quality Index (PSQI) global score, excluding the sleep-medication component (range, 0–18). Secondary Athens Insomnia Scale (AIS), HAMA, and wearable comparisons used Week 4 scores; the HUAWEI Band 8 estimated sleep stages and sleep score.

The between-arm difference in modified-PSQI change was −3.11 points (95% confidence interval, −4.11 to −2.11; p < 0.001), favoring active electroacupuncture. Mean sleep-quality scores fell in both arms, with a larger decrease under active treatment.

At Week 4, mean AIS and HAMA scores were lower with active treatment; the reported cutoffs mark symptom-scale thresholds, not confirmed diagnostic remission. Band 8 estimates favored active treatment for deep sleep, rapid eye movement (REM) sleep, and overall sleep score, while light sleep did not differ significantly. Trial-defined overall response began with at least a 25% reduction in PSQI score. Mild local bruising occurred in one patient per arm and resolved without intervention; treatment acceptability was high. No participant started a sleep medicine or changed an existing psychotropic dose during the intervention.

Both groups received CBT-I, and there was no CBT-I-only arm. The real-versus-sham comparison therefore cannot fully separate specific electroacupuncture effects from nonspecific procedural effects or establish a benefit relative to CBT-I alone. Follow-up was short, leaving durability unknown. The Shanghai-only setting, unmasked acupuncturists, and sample size limit inference about broader populations and uncommon harms. Band 8 sleep-stage estimates were exploratory and were not independently validated in this cancer population. The modified PSQI excludes an original component, so full-scale cutoffs do not transfer directly; the sample-size planning assumption was not a universal threshold for clinically important change. Cancer types varied, while chemotherapy and corticosteroid exposure were incompletely characterized and concomitant medication use was not quantitatively compared between arms.

The authors reported better short-term sleep-quality, insomnia, and anxiety measures with electroacupuncture plus CBT-I than with sham plus CBT-I during gynecological cancer chemotherapy. They called for larger multicenter trials with longer follow-up.

Clinician Questions

Which acupuncture points and electrical settings were used for insomnia and anxiety during gynecological cancer chemotherapy?

For patients with gynecological cancer receiving chemotherapy and CBT-I, investigators placed active electroacupuncture needles at Baihui (GV20), Shenting (GV24), Yintang (EX-HN3), and Shenmen (HT7). They applied 2-Hz current between Baihui and Yintang for 30 minutes per session, adjusted to comfort.

Was a generalized anxiety disorder diagnosis required for gynecological cancer patients receiving electroacupuncture and CBT-I?

Eligibility required anxiety symptoms defined by a HAMA score >14, not a formal DSM-5 generalized anxiety disorder diagnosis.